Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 8/20 | 0.47 |
| ▸ | CCND1 | P24385 | 8/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.47 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553699 | 0.95 | CDK4 (0.45) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL13553629 | 0.90 | CDK4 (0.60) | CDK4CCND1FGFR1FGFR4CCNA2 | |
| SCHEMBL14682091 | 0.85 | CDK4 (0.41) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL13553860 | 0.84 | CDK4 (0.40) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL13553519 | 0.84 | PKN1 (0.57) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL14681938 | 0.81 | MAP4K3 (0.46) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15785310 | 0.80 | PAK4 (0.44) | JAK2BRD4JAK3CDK4CCND1 | |
| SCHEMBL14693003 | 0.79 | JAK2 (0.42) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL15281102 | 0.79 | JAK2 (0.44) | JAK2BRD4JAK3JAK1BRD2 | |
| SCHEMBL13553481 | 0.79 | JAK2 (0.43) | JAK2BRD4JAK3JAK1BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | JAK2 505/4885BRD4 418/4885JAK3 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.